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Regulation of Immunoproteasome 
Function in the Lung
Ilona E. Keller1, Oliver Vosyka1, 2, Shinji Takenaka1, Alexander Kloß3, Burkhardt Dahlmann3, 
Lianne I. Willems4, Martijn Verdoes4, †, Hermen S. Overkleeft4, Elisabeth Marcos5, 
Serge Adnot5, Stefanie M. Hauck2, Clemens Ruppert6, Andreas Günther6, 7, Susanne Herold8, 
Shinji Ohno9, ‡, Heiko Adler9, Oliver Eickelberg1 & Silke Meiners1
Impaired immune function contributes to the development of chronic obstructive pulmonary disease 
(COPD). Disease progression is further exacerbated by pathogen infections due to impaired immune 
responses. Elimination of infected cells is achieved by cytotoxic CD8+  T cells that are activated by 
MHC I-mediated presentation of pathogen-derived antigenic peptides. The immunoproteasome, 
a specialized form of the proteasome, improves generation of antigenic peptides for MHC I 
presentation thereby facilitating anti-viral immune responses. However, immunoproteasome 
function in the lung has not been investigated in detail yet. In this study, we comprehensively 
characterized the function of immunoproteasomes in the human and murine lung. Parenchymal 
cells of the lung express low constitutive levels of immunoproteasomes, while they are highly and 
specifically expressed in alveolar macrophages. Immunoproteasome expression is not altered in 
whole lung tissue of COPD patients. Novel activity-based probes and native gel analysis revealed that 
immunoproteasome activities are specifically and rapidly induced by IFNγ treatment in respiratory 
cells in vitro and by virus infection of the lung in mice. Our results suggest that the lung is potentially 
capable of mounting an immunoproteasome-mediated efficient adaptive immune response to 
intracellular infections.
The lung is constantly exposed to acute environmental agents such as noxious gases, aerosols, and patho-
gens1. Efficient clearance and defense mechanisms are thus indispensable to protect the lung from injury 
and maintain lung function. Failure of these defense mechanisms results in sustained inflammation 
and activation of the immune system, contributing to chronic pulmonary diseases with impaired lung 
structure and function2. This is particularly evident for chronic obstructive pulmonary disease (COPD): 
lungs of COPD patients show increased levels of inflammatory cytokines such as tumor necrosis factor 
α (TNFα ) and interferon-γ (IFNγ ) as well as increased numbers of both innate and adaptive immune 
cells2,3. In addition, bacterial or viral infections in COPD patients often result in acute exacerbations and 
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accelerate disease progression, suggesting that, amongst others, the adaptive immune system is unable to 
efficiently detect and eliminate infected lung cells to terminate pathogen amplification. Intracellular anti-
gens are detected by pathogen-specific activated CD8+  T cells that patrol the lungs for pathogen-derived 
peptides presented in complex with major histocompatibility complex (MHC) I on the cell surface of 
infected cells.
The ubiquitin-proteasome system is the major peptide provider for MHC I antigen presentation. It 
degrades more than 90 % of all cellular proteins - including old and damaged ones - into small pep-
tides4–6. The proteasome consists of a barrel-shaped 20S proteolytic core particle which is activated by 
different proteasome regulators to form for instance the 26S, which degrades poly-ubiquitinated proteins 
in an ATP-dependent manner, and hybrid proteasomes7. The 20S core is composed of four heptameric 
rings comprising α - and β -subunits with α 7β 7β 7α 7 structure. In standard proteasomes, three of the seven 
β -subunits - namely β 1, β 2, and β 5 - exhibit proteolytic activity. A replacement of these β -subunits by 
their immunosubunit counterparts, i.e. low molecular mass protein (LMP) 2, multicatalytic endopepti-
dase complex-like 1 (MECL-1), and LMP7, also termed β 1i, β 2i, and β 5i, respectively, results in formation 
of so-called immunoproteasomes. Immunoproteasomes are constitutively present in lymphoid cells but 
their synthesis can be induced rapidly also in non-immune cells by IFNγ , or TNFα , e.g. upon viral or 
bacterial infection8. The newly assembled immunoproteasomes have altered cleavage kinetics compared 
to their 20S standard counterparts and generate antigenic peptides that are preferentially presented by 
MHC I molecules9. As such, rapid and specific induction of immunoproteasomes is required for efficient 
elimination of infected cells via the adaptive immune system. Increasing evidence suggests impairment of 
proteasome function by smoke exposure and in COPD10–13, however, until now it is not known whether 
immunoproteasome function is affected as well. Moreover, cell-specific expression of immunoproteas-
omes in the lung has not been analyzed so far and it is unclear to which degree immunoproteasome 
activity can be induced upon virus infection in vivo.
In this study, we comprehensively characterized immunoproteasome function, i.e. activity, in the lung 
by dissecting IFNγ -mediated regulation of specific catalytic activities of the immunoproteasome in dif-
ferent respiratory cell types in vitro and upon MHV-68 infection of the lung in vivo.
Results
Immunoproteasome expression in the murine lung. As immunoproteasome expression in the 
lung has not been investigated in detail so far, we first examined total expression levels of immunoprotea-
some subunits in the murine lung compared to liver and spleen including tissues from LMP2 and LMP7 
deficient mice as controls (Fig. 1a). Wildtype lungs contained intermediate amounts of the immunopro-
teasomal subunits LMP2 and LMP7 compared to liver and spleen. While LMP7 levels were unchanged 
in LMP2 deficient mice, LMP2 protein levels were evidently decreased in LMP7 deficient mice and the 
unprocessed pro-form of LMP2 accumulated in spleens of LMP7 deficient mice. To confirm incorpo-
ration of immunoproteasome subunits into active 20S proteasomes and their relative distribution com-
pared to standard β -subunits, we next isolated active 20S proteasomes from the lungs of healthy wildtype 
mice via sucrose-gradient fractionation and separated them on a 2D gel (Fig.  1b and Supplementary 
Fig. S1). By mass spectrometry of excised spots, we detected all different 14 subunits of the 20S protea-
some. All three immunoproteasome subunits were present in addition to the three standard proteasome 
subunits β 1, β 2, and β 5. Each immunoproteasome subunit was identified from three distinct spots, indi-
cating post-translational modifications of these subunits.
To specify the pulmonary cell types that contain immunoproteasomes, we stained murine lungs 
with LMP2- and LMP7-detecting antibodies using lungs of the respective knockout animals as con-
trols. Although we tested several commercially available antibodies, immunohistochemical detection of 
LMP7 proved to be unspecific as controlled by lungs of LMP7 knockout mice while staining for LMP2 
was specific (Fig.  1c): Alveolar epithelial and parenchymal cells of the lung expressed only very low 
amounts of LMP2, whereas alveolar macrophages were highly positive for this immunoproteasome sub-
unit. Individual cells in the vicinity of airways also exhibited prominent LMP2 staining.
Immunoproteasome expression is not altered between donor and COPD lungs. In a next 
step, we thoroughly investigated immunoproteasome expression in the human lung by using native 
PAGE and immunoblotting of human donor lung tissue. We unambiguously identified the immuno-
proteasome subunits LMP2 and LMP7 mainly in active 20S but also to some extent in 26S fractions as 
confirmed by blotting for respective proteasomal 19S (Rpt5) and 20S subunits (α 1-7) (Fig. 2a).
Immunohistochemical analysis of LMP2 in end-stage COPD tissue (GOLD stage III and IV) from 
explanted lungs revealed no obvious alteration in cell-type specific expression of LMP2 compared to 
lungs from human donors (Fig. 2b). We observed prominent but variable staining for LMP2 mainly in 
alveolar macrophages. While bronchial epithelial cells showed some positive staining, alveolar epithelial 
cells were negative for LMP2. In addition to alveolar macrophages, cells in the vicinity of airways also 
showed some LMP2 reactivity. However, our immunohistochemical staining was heterogeneous and did 
not allow a reliable quantification of LMP2 expression levels in lung tissue samples of COPD patients 
compared to controls.
In human lung tissue homogenates from cancer resections of never-smokers, ex-smokers, and COPD 
GOLD stage I and II classified patients, we again did not observe any significant difference in the levels 
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of LMP2 and LMP7 between these groups (Fig. 2c). Of note, expression of the 20S proteasome was also 
not altered in COPD tissue compared to non-COPD controls, indicating that the proteasome is not 
obviously dysregulated in these samples.
Active immunoproteasomes are induced by IFNγ in parenchymal cells of the lung. With the 
basal expression levels of immunoproteasomes being low in parenchymal cells, but high in immune cells 
of the lung, we next investigated to what extent immunoproteasomes can be induced in parenchymal 
cells by IFNγ , which has been shown as a major cytokine involved in acute virus infection and a major 
inducer of immunoproteasomes14. We confirmed IFNγ -mediated induction of immunoproteasomes in 
primary parenchymal cells of the murine and human lung: IFNγ strongly induced immunoproteasomal 
gene expression in mouse primary alveolar type II cells (pmATII) after 24 h of treatment (Fig. 3a). LMP2 
and LMP7 protein levels were both strongly induced in primary human (phLF) and mouse lung fibro-
blasts (pmLF) after IFNγ stimulation for 24 h (Fig. 3b). Similar to tissue homogenates shown in Fig. 1a, 
LMP7 was induced in fibroblasts from LMP2 deficient mice to the same degree as in wildtype mice, but 
the unprocessed pro-LMP2 accumulated in LMP7 deficient fibroblasts.
To define the kinetics and activities of newly formed immunoproteasomes after IFNγ stimulation in 
detail, we treated the human alveolar epithelial cell line A549 from 2 up to 72 h with IFNγ . mRNA levels 
of all three immunoproteasome subunits were upregulated after 2 h and further increased up to 24 h in 
Figure 1. Immunoproteasome expression in mouse lungs. (a) Immunoproteasome expression in 
homogenates of whole lung, liver, and spleen in C57BL/6 wildtype (wt), LMP2−/− or LMP7−/− mice. 
(b) Coomassie stained 2D-gel of purified 20S proteasomes from C57BL/6 mouse lungs. Protein 
spots were identified by mass spectrometry, immunoproteasome subunits are indicated in red. (c) 
Immunohistochemistry analysis of LMP2 expression in wildtype and LMP2−/− mice. Scale bar represents 
50 μ m.
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Figure 2. Immunoproteasome expression in human donor and COPD lungs. (a) Immunoproteasome 
expression in human donor lung lysate under native conditions. Native gels were blotted and LMP2, LMP7, 
α 1-7 subunits (20S), Rpt5 (19S) was detected with respective antibodies. (b) LMP2 staining of human lung 
sections from donors (n = 5) and COPD (n = 9) patients: (i) alveolar parenchyma, (ii) alveolar macrophages, 
(iii) bronchial epithelium with goblet cell hyperplasia in COPD. Scale bar represents 50 μ m. (c) Protein 
expression of immunoproteasome subunits LMP2 and LMP7 and total 20S (α 1-7) proteasomes in lungs of 
human organ donors (never-smoker or ex-smoker) and COPD patients.
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A549 cells upon IFNγ treatment (Fig. 4a). Transcript levels of NLRC5, a recently identified transactivator 
of LMP2 and MHC class I genes15, transiently peaked at 6 h but declined after 24 h (Fig. 4a).
Protein levels of both LMP2 and LMP7, were upregulated already after 6 h and stayed elevated until 
72 h after IFNγ treatment (Fig. 4b). The unprocessed pro-form of LMP2, which indicates that the protein 
is not yet incorporated into mature 20S proteasome complexes16, was detected between 6 and 24 h of 
IFNγ treatment suggesting that LMP2-containing immunoproteasomes are only finally assembled 48 h 
after IFNγ stimulation. As total 20S proteasome levels, however, were not altered, these results indicate 
a shift from standard 20S towards immunoproteasome expression in IFNγ -exposed lung alveolar cells 
(Fig. 4b). De novo assembly of active immunoproteasomes was further proven by use of activity-based 
probes (ABP). ABPs covalently bind to and label only active catalytic β -subunits of the intact 20S cat-
alytic core17. Here, we made use of three distinct site-specific ABPs that allowed us to discriminate the 
active standard and immunoproteasome subunits18. Native lysates of IFNγ -treated A549 were incubated 
with the respective ABPs and then separated under denaturing conditions to quantify the labeled cata-
lytic subunits of the proteasome: The activity of all three immunoproteasome subunits, LMP2, MECL-1, 
and LMP7, increased up to 24 h and slightly decreased at 72 h after IFNγ treatment while the standard 
catalytic subunits β 1, β 2, and β 5 were inversely regulated after an initial 24 h activation burst (Fig. 4c). 
The novel technique of ABP detection in native gels revealed ABP labeling of five different active 26S 
and hybrid proteasome complexes with a slight shift from active 26S to 20S proteasomes after 72 h of 
IFNγ treatment (Fig. 4d). LMP2 and LMP7 were incorporated into both, active 20S and 26S complexes, 
as shown by immunoblotting.
Active immunoproteasomes are induced by MHV-68 infection in the lung. As IFNγ -mediated 
induction of immunoproteasome is indispensable for efficient antigen presentation of viral proteins dur-
ing infection, we investigated the kinetics of immunoproteasome expression and activity in the lung after 
murine gammaherpesvirus-68 (MHV-68) infection in vivo. MHV-68 infection strongly induced immu-
noproteasome expression: mRNA levels of all three immunoproteasome subunits were highest at day 
14 post infection and declined to control levels after 148 days, even though IFNγ and TNFα transcript 
levels were still increased at that time point (Fig. 5a and Supplementary Fig. S3a). NLRC5 mRNA levels 
showed similar expression kinetics, but were still elevated after 148 days. Expression of standard protea-
some subunits was not obviously altered upon infection and even slightly decreased over time (Fig. 5b).
On the protein level, immunoproteasomes were strongly induced after 14 days and were still found 
to be slightly elevated 148 days after infection (Fig.  5c). The α 3 as well as the β 1 and β 2 constitutive 
subunits were also increased after 14 days of infection, although to a lesser extent (Fig. 5c). The inducible 
immunoproteasome subunits LMP2 and LMP7 were found in both, 20S and 26S, complexes, as deter-
mined by native gel immunoblotting (Fig.  5d). LMP2 staining of virus-infected mouse lungs revealed 
that the overall increase of LMP2 protein levels after 47 days was mainly attributable to enhanced LMP2 
expression in alveolar epithelial cells and alveolar macrophages (Fig. 5e).
ABP labeling of native lung lysates of infected mice revealed that the specific activity of LMP2 and 
MECL-1 was transiently increased during the course of infection and normalized to control levels after 
148 days (Fig.  6a). In these mouse samples, we were not able to discriminate LMP7 and β 5 activities 
as both mouse subunits have a similar molecular weight (Fig S2), different from the human subunits 
(Fig. 4). Of note, activity of standard subunits β 1 and β 2 was also increased, but to a lesser extent than 
their respective immunoproteasome subunit counterparts LMP2 and MECL-1 (Fig. 6a). The pronounced 
rise in specific immunoproteasome activity during the course of virus infection closely followed a tran-
sient increase in total proteasome activity with similar kinetics and resulted in a considerable shift from 
standard to immunoproteasome activity in these samples (Fig. 6b and Supplemental Fig. S3b).
Figure 3. Immunoproteasomes are induced by IFNγ in lung parenchymal cells. (a) mRNA fold change 
of 20S α 7-subunit and immunoproteasome subunits in primary mouse alveolar type II cells (pmATII) after 
24 h of IFNγ treatment compared to control. Results are combined data from three independent experiments 
(mean + /− SEM, Mann-Whitney-U test, * = p < 0.05). (b) Western Blot showing induction of LMP2 or 
LMP7 in primary mouse (wildtype (wt), LMP2−/−, or LMP7−/−; pmLF) and human donor lung fibroblasts 
(phLF) after 24 h of IFNγ treatment. Results are representative for two independent experiments.
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The increase in total proteasome activity was attributable to both 20S and 26S complexes by analysis 
of native PAGE of ABP-labeled lysates (Fig. 6c). Taken together, our data show prominent induction of 
active immunoproteasomes in the lung by IFNγ in different alveolar cell types and by virus infection 
in vivo indicating that these cells are able to mount efficient immunoproteasome-mediated immune 
responses to infection. Of note, while the kinetics of specific immunoproteasome activities were similar 
to the transcript kinetics of immunoproteasome subunits, activation of standard proteasome activity 
Figure 4. Immunoproteasome induction kinetics in alveolar epithelial cell line. (a) mRNA fold change 
of immunoproteasome subunits and their transcriptional activator NLRC5 in response to IFNγ (75 U/ml) 
after 2, 6, or 24 h in A549 cells. Results are the combined data of three independent experiments (mean + /− 
SEM, Kruskal-Wallis Test with Dunn’s Post Test, * = p < 0.05, ** = p < 0.01). (b) Time course of expression 
of immunoproteasome subunits LMP2 and LMP7 and total 20S α -subunits in native lysates of A549 cells 
from 6 up to 72 h after IFNγ treatment. Results are representative for three independent experiments. 
(c) Fluorescent ABP labeling of the same lysates as in (b) with MV151 (labeling all active β -subunits), 
LW124 (β 1 and LMP2 specific) or MVB127 (β 5 and LMP7 specific). Results are representative for three 
independent experiments. (d) Native gel analysis of A549 lysates + /− IFNγ treatment for 72 h: MV151-ABP 
analysis and Western Blot of native lysates with LMP2 and LMP7 antibodies. α 1-7 was used to detect 20S 
complexes, Rpt 5 (19S subunit) was used to detect 26S proteasome complexes. Results are representative for 
three independent experiments.
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upon acute virus infection did not involve transcriptional regulation but appears to take place on the 
post-transcriptional level.
Discussion
Immunoproteasomes play a pivotal role in MHC I antigen presentation. We thus investigated the func-
tion and plasticity of immunoproteasomes in human and mouse lungs as well as upon virus-infection.
Protein expression levels of immunoproteasomes in the mouse lung were comparable to those in the 
liver but lower than in mouse spleen. While we could specifically detect LMP2 and LMP7, immuno-
detection of the third immunoproteasome subunit MECL-1 was unspecific with several commercially 
available antibodies. Biochemical purification of lung 20S proteasomes revealed incorporation of both 
standard and immunoproteasome subunits into active 20S complexes. Of note, each of the three immu-
noproteasome subunits was found in three distinct protein spots indicating post-translational modifica-
tions or isoform expression in the mouse lung. However, our mass spectrometry analysis did not allow 
us to identify any modifications, which was beyond the scope of this project. Further analysis of native 
proteasome complexes in the lung by blotting of native PAGE gels revealed that 20S immunoproteasomes 
can be found both in the 20S and 26S proteasome fraction of mouse and human lungs (Figs. 2a, 4d and 
5d), implying that immunoproteasomes contribute to both ubiquitin-dependent (26S) and -independent 
(20S) degradation of proteins.
While other studies have examined total levels of immunoproteasomes in human tissue, whole rat 
lungs, and in LCMV-infected mouse lungs and other organs19–23, cell-specific expression in the lung has 
not yet been investigated23,24. Here, we show that the immunoproteasomal subunit LMP2 is expressed 
at low basal levels in lung parenchymal cells (alveolar type I and II cells, fibroblasts) and the bronchial 
epithelium but strongly expressed in alveolar macrophages (Figs. 1c and 2b). Specificity of our staining 
was confirmed in control lungs of LMP2 deficient mice (Fig.  1c). This is in line with a recent study 
that demonstrated expression of LMP2 and LMP7 in lung granulomas of sarcoidosis patients24. Our in 
vitro data show that primary alveolar type II cells and fibroblasts have the capability to express immu-
noproteasomes after IFNγ stimulation, thus enabling immunoproteasome-dependent antigen presenta-
tion. Interestingly, fibroblasts from LMP7 deficient mice express some unprocessed LMP2 compared to 
wildtype mice. It was previously shown that LMP7 is necessary for efficient incorporation of LMP225, 
which explains our observation of the presence of unprocessed LMP2 both after stimulation with IFNγ 
in vitro (Fig. 3b) as well as in spleen homogenates of LMP7 deficient mice (Fig. 1a). In A549 cells, the 
pro-form of LMP2 was detected until 24 h after IFNγ treatment, while pro-LMP7 was not detectable 
at any time-point (even though the LMP7 antibody we used detects both the unprocessed and mature 
form of LMP7). This might be due to preferential incorporation of pro-LMP7 into 20S compared to its 
standard proteasome counterpart pro-β 5, as suggested previously26,27.
Using a novel and specific set of activity-based probes18, we were able to dissect the six different 
active sites of the standard and immunoproteasome 20S, which specified immunoproteasome function 
in the lung. This is not possible with commercially available proteasome substrates. A striking feature 
of these activity-based probes is that beyond quantification of the three main proteasomal activities, we 
can specifically discriminate activities for the standard and the respective immunoproteasome subunit 
counterparts β 1/LMP2, β 2/MECL-1, and β 5/LMP7 as they are labeled within the same lysate (Fig. 4c). 
The novel combination of activity-based probe labeling of all catalytic active sites of the proteasome 
with native gel electrophoresis permitted us to assign newly assembled immunoproteasomes to active 
20S and 26S proteasome complexes (Fig. 4d). Using this innovative biochemical toolbox, we showed that 
IFNγ can rapidly induce expression and assembly of active immunoproteasomes in parenchymal cells 
of the lung. This cannot be achieved with conventional and commercially available proteasome activity 
assays. With these techniques at hand, we also assessed immunoproteasome activity in the course of 
virus infection of the lung. For that, we used the model of MHV-68, since intranasal infection of mice 
leads to productive virus replication in the lung accompanied by virus-induced cell damage and sub-
sequent development of pulmonary fibrosis28,29. Viral infections induce immunoproteasomes via IFNγ 
as part of the adaptive immune response to infections30 thereby facilitating the specific detection and 
targeted elimination of infected cells by the immune system: Pathogenic, e.g. viral, proteins are cleaved 
by immunoproteasomes into antigenic peptides for MHC I presentation14,31–34. MHC I epitopes are then 
recognized by specific cytotoxic CD8+ T cell clones that kill infected cells. To raise a specific clonal T 
cell response, antigen presenting cells (APC) in the lung take up pathogens and migrate to the lymph 
nodes to prime CD8+ T cells. Importantly, APCs and infected parenchymal cells need to present the same 
MHC I epitope to prime an efficient clonal CD8+ T cell response, respectively. As APCs constitutively 
express immunoproteasomes, IFNγ -mediated upregulation of immunoproteasomes in infected paren-
chymal cells is thus indispensable for mounting an efficient immune response against the pathogen14,31–35. 
In our MHV-68 infection model (Figs. 5 and 6), we were able to detect increased immunoproteasome 
transcript and protein levels which were highest 14 days after viral infection. While mRNA transcripts 
were back at baseline at day 148, protein levels of LMP2 and LMP7 were still increased, suggesting pro-
teasome stabilization and extended half-life of proteasomes after infection. This might also explain the 
observation of slightly increased standard proteasomes on the protein and activity levels at day 14, which 
cannot be explained by increased transcript levels (Figs. 5 and 6). Total proteasome activity, as assessed 
by fluorescent activity-based probes, was transiently increased up to twofold during infection and was 
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Figure 5. Murine gammaherpesvirus-68 (MHV-68) infection induces immunoproteasomes in the lung. 
(a) and (b) relative mRNA levels of standard proteasome subunits α 7, β 1, β 2, β 5 and immunoproteasome 
subunits LMP2, MECL-1, LMP7 and MHC I gene transactivator NLRC5 in the lungs of MHV-68 
infected mice (day 14, 48 and 148 post infection) compared to mock-infected controls, Rpl19 served as 
housekeeping gene, n = 3 per group (mean + /− SEM, Kruskal-Wallis Test with Dunn’s Post Test, * = 
p < 0.05, ** = p < 0.01). (c) Western Blot analysis of LMP2, LMP7, α 3, β 1 and β 2 protein expression 
of whole lung homogenate of MHV-68 infected mice (day 14, 48 and 148) compared to uninfected 
controls. (d) Native Western Blot of lung lysates from uninfected or MHV-68 infected mice after 14 days. 
(e) Immunohistochemistry analysis of LMP2 expression in wildtype lung slices at 47 dpi. All results are 
representative for two independent experiments. dpi, days post infection.
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back at baseline after 148 days. The increase in proteasome activity was attributed to an increase in both 
20S and 26S activities which both comprised the virus-induced immunoproteasome subunits LMP2 and 
LMP7. These data suggest ubiquitin-dependent and -independent degradation of proteins by immuno-
proteasomes during infection.
Over the course of infection, we observed a shift in standard versus immunoproteasome activity in 
MHV-68 infection, which was resolved for the catalytic subunit pair MECL-1/β 2, but not for LMP2/β 1 
subunits (Fig.  6b). This indicates that virus infection has a long-term effect on antigen processing by 
immunoproteasomes. In part, this might be explained by the nature of MHV-68 infection, which can 
persist latently in lung epithelial cells and macrophages36,37 and can be spontaneously reactivated. An 
indicator for such reactivation is the still increased level of IFNγ 148 days post infection.
Figure 6. Immunoproteasome and standard proteasome activities in the lung during course of  
MHV-68 infection. (a) Activity-based probe labeling of native whole lung lysates of infected mice (mock, 14, 
48, 148 dpi) with MV151 (labeling all active β -subunits), LW124 (β 1 and LMP2 specific) and densitometric 
analysis of MECL-1, β 2, LMP2 and β 1, depicted as fold increase over uninfected mice. (b) Activity ratios 
of intensities of MECL-1/β 2 and LMP2/β 1. (c) Native gel analysis of lung lysates labeled with activity-based 
probe MV151. (mean + /− SEM, Kruskal-Wallis Test with Dunn’s Post Test, * = p < 0.05, ** = p < 0.01). All 
results are representative for two independent experiments. dpi, days post infection.
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COPD is characterized by loss of parenchymal tissue, chronic bronchitis, and bacterial colonization 
of the lower airways2. Respiratory infections exacerbate COPD pathology. Smokers and COPD patients 
suffer longer from respiratory infections and need more time to resolve them38. Accordingly, it has been 
shown that cigarette smoke, the main risk factor for COPD, generally dampens the host’s immune system 
in response to infections as it interferes with STAT-1 and IRF-3 immune signaling39–43. Cigarette smoke 
has also been shown to affect adaptive immune responses such as MHC II antigen presentation2,44. The 
role of the MHC I antigen presentation machinery in COPD in general and in viral exacerbations in 
particular has not been investigated so far. In this study, we did not detect increased levels of immuno-
proteasomes in early-staged COPD lungs (Fig.  2c). While Fujino et al. observed increased LMP2 and 
LMP7 transcript levels in primary alveolar type II cells of patients with early COPD stages, a recent 
study observed no differential expression of immunoproteasomes in lungs of end-stage COPD patients 
compared to controls23,45. This accords with our immunohistochemical analysis of end-stage-diseased 
COPD tissue, which did not reveal upregulation of the immunoproteasomal LMP2 subunit in alveolar 
epithelial cells. High immunoproteasome expression in alveolar macrophages, as observed here, may also 
account for extracellular immunoproteasomes in the BAL fluid of patients with acute respiratory distress 
syndrome46. We also did not observe any consistent change in standard versus immunoproteasome activ-
ities in early and late stage COPD lungs (data not shown). Overall proteasome activity has been assessed 
previously in COPD lungs using conventional proteasome activity assays with conflicting results: While 
Baker et al. did not observe significantly altered levels and activities in COPD lungs, Malhotra et al. 
reported that proteasome expression and activity declined and strongly associated with the severity of 
lung dysfunction in COPD patients12,23. However, as the corresponding author has recently expressed his 
concern on anomalies in figures in this article, this study has to be considered with caution47. It is well 
established though that proteasome activity can be impaired by cigarette smoke which may then add to 
development and progression of COPD10,11.
In this study, we show that lung parenchymal cells express immunoproteasomal subunits at low basal 
levels, but they can be rapidly induced to form active immunoproteasomes upon IFNγ stimulation in 
vitro or MHV-68 infection in vivo. This suggests that the lung is potentially capable of mounting an 
efficient adaptive immune response to intracellular infections.
Methods
Human lung tissue. For protein extraction, human lung tissue from never-smokers (n = 3), ex-smokers 
(n = 4), and COPD patients (n = 6) undergoing lung resection surgery for localized lung tumors was col-
lected as previously described48. This study was approved by the institutional review board of the Henri 
Mondor Teaching Hospital (Créteil, France; AFSSAPS reference number B90895-60). All patients and 
control subjects signed an informed consent document before study inclusion. Paraffin-embedded lung 
sections of human lung transplant donors (n = 5) or COPD patients (n = 9) with end-stage disease were 
obtained from the Department of Thoracic Surgery in Vienna, Austria, as described elsewhere49. The 
study protocol was approved by the Ethics Committee of the Justus-Liebig-University School of Medicine 
(No. 31/93, 84/93, 29/01) and the University of Vienna Hospital ethics committee (EK-Nr 076/2009).
Animals. Tissues or cells were isolated from C57BL/6 wildtype (Charles River Laboratories), LMP2−/− 
(Psmb9tm1Stl, 50), or LMP7−/−(Psmb8tm1Hjf, 51) mice. All animal procedures were conducted according to 
international guidelines and with approval of the Bavarian Animal Research Authority in Germany. 
All surgery was performed under ketamine/xylazine anesthesia, and all efforts were made to minimize 
suffering.
Virus infection of mice. 8-12 week old female C57BL/6 mice were anesthetized using ketamine/xyla-
zine and infected intranasally with 5 × 104 plaque forming units (PFU) of murine gammaherpesvirus-68 
(MHV-68) as described elsewhere52. Animals were sacrificed after 14, 48, or 148 days, uninfected mice 
served as controls and were sacrificed together with the 14 days infected mice, the group size was three 
per group. Mice were housed in individually ventilated cages during the MHV-68 infection period. All 
animal experiments were in compliance with the German Animal Welfare Act, and the protocol was 
approved by the local Animal Care and Use Committee (District Government of Upper Bavaria; permit 
number 124/08).
Cell culture and reagents. The human A549 alveolar epithelial cell line was obtained from ATCC 
(ATCC® CCL-185™, American Type Culture Collection, Manassas, VA, USA). Cells were cultured in 
DMEM (21885025, Life Technologies, Carlsbad, CA, USA) supplemented with 10 % fetal bovine serum 
(FBS, P30-3702, PAN Biotech, Aidenbach, Germany) and 100 U/ml of Pen/Strep (15070063, Life 
Technologies) and cells were grown at 37 °C in a humidified atmosphere containing 5 % CO2. Human 
or mouse recombinant IFNγ (11040596001/11276905001, Roche, Basel, Switzerland) was used at con-
centrations of 75 U/ml.
Activity-based probe labeling. Activity of the constitutive and immunoproteasome subunits was 
monitored by using a set of activity-based probes (ABP)53. The pan-reactive proteasome ABP MV15117 
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was used for assessing of β 2/MECL-1 activities, LW124 for β 1/LMP2 activity, and MVB127 was used to 
label β 5/LMP718. Hypoosmotic native lysates of total lung or A549 cells were diluted to a total protein 
concentration of 0.5 μ g/μ l with reaction buffer (50 mM HEPES pH 7.4, 100 mM KCl, 10 mM MgCl2). By 
shaking at 37 °C for 1 h, 30 μ l of sample was incubated with 0.5 μ M MV151, 0.25 μ M LW124 or 1 μ M 
MVB127, respectively, and subsequently quenched by the addition of 6x Laemmli (50 % v/v glycerol, 
300 mM Tris·HCl, 6 % w/v SDS, 325 mM DTT, 0.1 % w/v bromophenol blue, pH 6.8) or 5x native loading 
buffer (50 % v/v glycerol, 250 mM Tris, 0.1 % w/v bromophenol blue, pH 7.5) to a final 1x concentra-
tion. Samples were separated on 15 % Tris-glycine SDS polyacrylamide gels or non-denaturing 3–8 % 
Tris-Acetate gels (Life Technologies) and active proteasome subunits were visualized using a fluorescent 
scanner (Typhoon TRIO+ ; Amersham biosciences). Images were taken at 450 PTM and 50 μ m pixel 
resolution with fluorescence Cy3/TAMRA for ABPs MV151 and MVB127 while the Cy2 florescent chan-
nel was used for LW124 and analyzed by using ImageJ software. Equal sample loading was verified by 
staining gels with PageBlueTM (24620, Fisher Scientific, Schwerte, Germany).
Statistics and Software. Data were analyzed with Image LabTM (Version 3.0.1., Bio-Rad, Hercules, 
CA, USA), ImageJ (ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA), or Prism5 
(Version 5.0, GraphPad Software, Inc., La Jolla, CA, USA). Statistics were performed using Prism5 with 
non-parametric tests and appropriate post hoc-analysis. P-values < 0.05 were considered statistically sig-
nificant.
Additional detail on the methods is provided in an online data supplement.
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